Effects of patient selection on the applicability of results from a randomised clinical trial (EORTC 10853) investigating breast-conserving therapy for DCIS

British Journal of Cancer

Volumn 87, Issue 6, 2002, Pages 615-620

  Bijker, N ^a   Peterse, J L ^a   Fentiman, I S ^b   Julien, J P ^c   Hart, A A M ^a   Avril, A ^d   Cataliotti, L ^e   Rutgers, E J T ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b GUY S HOSPITAL   (United Kingdom)

^c CENTRE HENRI BECQUEREL   (France)

^d INSTITUT BERGONIÉ   (France)

^e Policlinico di Careggi   (Italy)

Author keywords

Breast conserving therapy; Ductal carcinoma in situ (DCIS); Patient selection; Randomised clinical trial

Indexed keywords

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CARCINOMA IN SITU; CONTROLLED STUDY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MASTECTOMY; PATIENT COMPLIANCE; PATIENT SELECTION; PRIORITY JOURNAL; RECURRENCE RISK; TREATMENT OUTCOME;

AGED; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; FEMALE; HUMANS; MULTICENTER STUDIES; PATIENT SELECTION; PROSPECTIVE STUDIES; RADIOTHERAPY, ADJUVANT; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 0037048327     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600514     Document Type: Article

References (30)

1. Anonymous (1994) From research to practice. Lancet 344: 417-418
2. Anonymous (1986) Results of chemotherapy for unselected patients with acute myeloblastic leukaemia: effect of exclusions on interpretation of results. The Toronto Leukemia Study Group. Lancet 1: 786-788
3. Bellamy CO, McDonald C, Salter DM, Chetty U, Anderson TJ (1993) Noninvasive ductal carcinoma of the breast: The relevance of histologic categorization. Hum Pathol 24: 16-23
4. Bijker N, Peterse JL, Duchateau L, Julien J-P, Dural C, Di Palma S, Simony-Lafontaine J, De Mascarel I, Van de Vijver MJ (2001) Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma in situ: analysis of European Organization for Research and Treatment of Cancer trial 10853. J Clin Oncol 19: 2263-2271
5. Cataliotti L, Distante V, Ciatto S, Bianchi S, Pacini P, Simoncini R, Rosselli Del Turco M, Cardona G, Falli F (1992) Intraductal breast cancer: review of 183 consecutive cases. Eur J Cancer 28A: 917-920
6. Ellenberg JH (1994) Selection bias in observational and experimental studies. Stat Med 13: 557-567
7. Eusebi V, Feudale E, Foschini MP, Micheli A, Conti A, Riva C, Di Palma S, Rilke F (1994) Long-term follow-up of in situ carcinoma of the breast. Semin Diagn Pathol 11: 223-235
8. Fentiman IS, Julien JP, van Dongen JA, van Geel B, Chetty U, Coibion M (1991) Reasons for non-entry of patients with DCIS of the breast into a randomized trial (EORTC 10853). Eur J Cancer 27: 450-452
9. Fisher B (1991) On clinical trial participation. J Clin Oncol 9: 1927-1930
10. Gorst DW, Johnson KW (1992) Survival in adult leukaemia. Clin Lab Haematol 14: 99-108
11. Holland R, Peterse JL, Millis RR, Eusebi V, Faverly D, van de Vijver MJ, Zafrani B (1994) Ductal carcinoma in situ: a proposal for a new classification. Semin Diagn Pathol 11: 167-180
12. Jack WJ, Chetty U, Rodger A (1990) Recruitment to a prospective breast conservation trial: why are so few patients randomized? BMJ 301: 83-85
13. Julien J-P, Bijker N, Fentiman IS, Peterse JL, Delledonne V, Rouanet P, Avril A, Sylvester R, Mignolet F, Bartelink H, Van Dongen JA (2000) Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomised phase III trial 10853. Lancet 355: 528-533
14. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481
15. Kober L, Torp-Pedersen C (1995) Clinical characteristics and mortality of patients screened for entry into the Trandolapril Cardiac Evaluation (TRACE) study. Am J Cardiol 76: 1-5
16. Kotwall CA, Mahoney LJ, Myers RE, DeCoste L (1992) Reasons for non-entry in randomized clinical trials for breast cancer: a single institutional study. J Surg Oncol 50: 125-129
17. Lagios MD, Margolin FR, Westdahl PR, Rose MR (1989) Mammographically detected duct carcinoma in situ. Frequency of local recurrence following tylectomy and prognostic effect of nuclear grade on local recurrence. Cancer 63: 618-624
18. Lee JY, Breaux SR (1983) Accrual of radiotherapy patients to clinical trials. Cancer 52: 1014-1016
19. Licht RW, Gouliaev G, Vestergaard P, Frydenberg M (1997) Generalisability of results from randomized drug trials. A trial on antimanic treatment. Br J Psychiatry 170: 264-267
20. Martin JF, Henderson WG, Zacharski LR, Rickles FR, Forman WB, Cornell CJ, Forcier RJ, Edwards RL, Headley E, Kim SH (1984) Accrual of patients into a multihospital Cancer clinical trial and its implications on planning future studies. Am J Clin Oncol 7: 173-182
21. McCusker J, Wax A, Bennett JM (1982) Cancer patient accessions into clinical trials: a pilot investigation into some patient and physician determinants of entry. Am J Clin Oncol 5: 227-236
22. Olschewski M, Scheurlen H (1985) Comprehensive Cohort Study: an alternative to randomized consent design in a breast preservation trial. Methods Inf Med 24: 131-134
23. Page DL, Dupont WD, Rogers LW, Landenberger M (1982) Intraductal carcinoma of the breast: follow-up after biopsy only. Cancer 49: 751-758
24. Partonen T, Sihvo S, Lonnqvist JK (1996) Patients excluded from an antidepressant efficacy trial. J Clin Psychiatry 57: 572-575
25. Silverstein MJ, Waisman JR, Gamagami P, Gierson ED, Colburn WJ, Rosser RJ, Gordon PS, Lewinsky BS, Fingerhut A (1990) Intraductal carcinoma of the breast (208 cases). Clinical factors influencing treatment choice. Cancer 66: 102-108
26. Silverstein MJ, Barth A, Poller DN, Gierson ED, Colburn WJ, Waisman JR, Gamagami P (1995) Ten-year results comparing mastectomy to excision and radiation therapy for ductal carcinoma in situ of the breast. Eur J Cancer 31A: 1425-1427
27. Silverstein MJ, Lagios MD, Groshen S, Waisman JR, Lewinsky BS, Martino S, Gamagami P, Colburn WJ (1999) The influence of margin width on local control of ductal carcinoma in situ of the breast. N Engl J Med 340: 1455-1461
28. Taylor KM, Margolese RG, Soskolne CL (1984) Physicians' reasons for not entering eligible patients in a randomized clinical trial of surgery for breast cancer. N Engl J Med 310: 1363-1367
29. Warneke J, Grossklaus D, Davis J, Stea B, Bebb G, Taylor C, Hastings R, Villar H (1995) Influence of local treatment on the recurrence rate of ductal carcinoma in situ. J Am Coll Surg 180: 683-688
30. Williams CJ, Zwitter M (1994) Informed consent in European multicentre randomized clinical trials - are patients really informed?. Eur J Cancer 30A: 907-910